Caspian Journal of Internal Medicine
Babol University of Medical Sciences
Fri, Feb 7, 2025
[Archive]
Volume 11, Issue 2 (3-2020)
Caspian J Intern Med 2020, 11(2): 124-134 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ebrahimi P, Farhadi Z, Bahzadifar M, Shabaninejad H, gorji H A, Tahermi mirghaed M, et al . Prevalence rate of aspirin resistance in cardiovascular disease patients: A systematic review and meta-analysis. Caspian J Intern Med 2020; 11 (2) :124-134
URL: http://caspjim.com/article-1-1732-en.html
URL: http://caspjim.com/article-1-1732-en.html
Parvin Ebrahimi 
, Zeynab Farhadi * , Masoud Bahzadifar , Hosein Shabaninejad , Hasan abolghasem Gorji , Masood Tahermi mirghaed , Morteza Salemi , Kamyar Amin , Roghayeh Mohammadibakhsh , Nicola Luigi Bragazzi , Rahim Sohrabi
, Zeynab Farhadi * , Masoud Bahzadifar , Hosein Shabaninejad , Hasan abolghasem Gorji , Masood Tahermi mirghaed , Morteza Salemi , Kamyar Amin , Roghayeh Mohammadibakhsh , Nicola Luigi Bragazzi , Rahim Sohrabi
Department of Health Services Management, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran , farhadi_zeynab@yahoo.com
Abstract: (9662 Views)
Background: Cardiovascular disease (CVD) is the first cause of mortality worldwide, with all the healthcare systems facing this very challenging issue. Aspirin continues to be the major gold-standard treatment worldwide in the prevention of thrombotic disease in patients with CVD, even though not all individuals respond to antiplatelet therapy in a similar way, being resistant to aspirin. The aim of this study was to determine the prevalence of laboratory defined aspirin resistance in CVD patients worldwide.
Methods: Relevant articles were identified through searching EMBASE, PubMed/ MEDLINE, ISI /Web of Science, Scopus, and the Cochrane Library, from January 2000 to February 2018. The methodological quality of the included studies was critically appraised using the Newcastle-Ottawa scale. The pooled prevalence of laboratory defined aspirin resistance was computed using the Der Simonian-Laird random-effect model.
Results: We included 65 studies, with a total of 10,729 patients. The overall prevalence of laboratory defined aspirin resistance in CVD patients was 24.7% ([95%CI 21.4-28.4]. Women were found to be at increased risk of laboratory defined aspirin resistance compared to men, with an odds ratio of 1.16 [95%CI 0.87-1.54].
Conclusion: Doctors and healthcare providers should pay special attention to aspirin resistance since lack of awareness could cause problems and increase mortality in these patients, if not properly treated with higher aspirin doses.
Methods: Relevant articles were identified through searching EMBASE, PubMed/ MEDLINE, ISI /Web of Science, Scopus, and the Cochrane Library, from January 2000 to February 2018. The methodological quality of the included studies was critically appraised using the Newcastle-Ottawa scale. The pooled prevalence of laboratory defined aspirin resistance was computed using the Der Simonian-Laird random-effect model.
Results: We included 65 studies, with a total of 10,729 patients. The overall prevalence of laboratory defined aspirin resistance in CVD patients was 24.7% ([95%CI 21.4-28.4]. Women were found to be at increased risk of laboratory defined aspirin resistance compared to men, with an odds ratio of 1.16 [95%CI 0.87-1.54].
Conclusion: Doctors and healthcare providers should pay special attention to aspirin resistance since lack of awareness could cause problems and increase mortality in these patients, if not properly treated with higher aspirin doses.
Type of Study: Review Article |
Subject:
Cardiology
Received: 2020/02/2 | Accepted: 2019/03/7 | Published: 2020/04/22
Received: 2020/02/2 | Accepted: 2019/03/7 | Published: 2020/04/22
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
